Back to search results
NCT03683186

A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension

Enrolling by Invitation
PHASE3Ages 18+InterventionalTreatment
United Therapeutics
~1,000 participants
Updated 2026-02-20 on ClinicalTrials.gov
What's tested:Ralinepag

At a glance

Recruiting sites
0 of 190 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of subjects with treatment-emergent adverse events [Safety and Tolerability]
Measured over Up to 6 years

Conditions

PAH
Pulmonary Hypertension
Pulmonary Arterial Hypertension
Hypertension
Connective Tissue Diseases
Familial Primary Pulmonary Hypertension
Vascular Diseases
Cardiovascular Diseases
Hypertension, Pulmonary
Lung Diseases
Respiratory Tract Disease

Explore related trials

Connective Tissue Disease-Associated Pulmonary Arterial HypertensionHeritable Pulmonary Arterial HypertensionPulmonary Arterial Hypertension

Where it's being run

190 sites across 96 states
Argentina9
California8
Italy7
New South Wales5
Israel5
Poland5
Texas4
France4

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

What this trial measures

  • Number of subjects with treatment-emergent adverse events [Safety and Tolerability]Up to 6 years

    The safety and tolerability of ralinepag will be evaluated by the Number of subjects with treatment-emergent adverse events